Literature DB >> 26676850

Toll-like receptor 3 signalling mediates angiogenic response upon shock wave treatment of ischaemic muscle.

Johannes Holfeld1, Can Tepeköylü1, Christin Reissig2, Daniela Lobenwein1, Bertram Scheller2, Elke Kirchmair1, Radoslaw Kozaryn1, Karin Albrecht-Schgoer3, Christoph Krapf1, Karin Zins4, Anja Urbschat5, Kai Zacharowski2, Michael Grimm1, Rudolf Kirchmair3, Patrick Paulus6.   

Abstract

AIMS: Shock wave therapy (SWT) represents a clinically widely used angiogenic and thus regenerative approach for the treatment of ischaemic heart or limb disease. Despite promising results in preclinical and clinical trials, the exact mechanism of action remains unknown. Toll-like receptor 3, which is part of the innate immunity, is activated by binding double-stranded (ds) RNA. It plays a key role in inflammation, a process that is needed also for angiogenesis. We hypothesize that SWT causes cellular cavitation without damaging the target cells, thus liberating cytoplasmic RNA that in turn activates TLR3. METHODS AND
RESULTS: SWT induces TLR3 and IFN-β1 gene expression as well as RNA liberation from endothelial cells in a time-dependant manner. Conditioned medium from SWT-treated HUVECs induced TLR3 signalling in reporter cells. The response was lost when the medium was treated with RNase III to abolish dsRNAs or when TLR3 was silenced using siRNAs. In a mouse hind limb ischaemia model using wt and TLR3(-/-) mice (n = 6), SWT induced angiogenesis and arteriogenesis only in wt animals. These effects were accompanied by improved blood perfusion of treated limbs. Analysis of main molecules of the TLR3 pathways confirmed TLR3 signalling in vivo following SWT.
CONCLUSION: Our data reveal a central role of the innate immune system, namely Toll-like receptor 3, to mediate angiogenesis upon release of cytoplasmic RNAs by mechanotransduction of SWT. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2015. For permissions please email: journals.permissions@oup.com.

Entities:  

Keywords:  Angiogenesis; Shock wave therapy; Toll-like receptor 3

Mesh:

Substances:

Year:  2015        PMID: 26676850     DOI: 10.1093/cvr/cvv272

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  19 in total

Review 1.  Transflammation: Innate immune signaling in nuclear reprogramming.

Authors:  Shu Meng; Palas Chanda; Rajarajan A Thandavarayan; John P Cooke
Journal:  Adv Drug Deliv Rev       Date:  2017-09-13       Impact factor: 15.470

2.  Efficacy and safety of cardiac shock wave therapy for patients with severe coronary artery disease: A randomized, double-blind control study.

Authors:  Na Jia; Ruisheng Zhang; Baoyi Liu; Bing Liu; Xin Qi; Ming Lan; Junmeng Liu; Ping Zeng; Congxia Chen; Wenchan Li; Yue Guo; Zhiming Yao; Qing He
Journal:  J Nucl Cardiol       Date:  2021-09-02       Impact factor: 3.872

3.  Shock waves promote spinal cord repair via TLR3.

Authors:  Can Gollmann-Tepeköylü; Felix Nägele; Michael Graber; Leo Pölzl; Daniela Lobenwein; Jakob Hirsch; Angela An; Regina Irschick; Bernhard Röhrs; Christian Kremser; Hubert Hackl; Rosalie Huber; Serena Venezia; David Hercher; Helga Fritsch; Nikolaos Bonaros; Nadia Stefanova; Ivan Tancevski; Dirk Meyer; Michael Grimm; Johannes Holfeld
Journal:  JCI Insight       Date:  2020-08-06

4.  Neuronal Pre- and Postconditioning via Toll-like Receptor 3 Agonist or Extracorporeal Shock Wave Therapy as New Treatment Strategies for Spinal Cord Ischemia: An In Vitro Study.

Authors:  Daniela Lobenwein; Rosalie Huber; Lars Kerbler; Alexandra Gratl; Sabine Wipper; Can Gollmann-Tepeköylü; Johannes Holfeld
Journal:  J Clin Med       Date:  2022-04-11       Impact factor: 4.964

Review 5.  Mesenchymal stem cells as therapeutic target of biophysical stimulation for the treatment of musculoskeletal disorders.

Authors:  Marco Viganò; Valerio Sansone; Maria Cristina d'Agostino; Pietro Romeo; Carlotta Perucca Orfei; Laura de Girolamo
Journal:  J Orthop Surg Res       Date:  2016-12-16       Impact factor: 2.359

6.  Shockwaves prevent from heart failure after acute myocardial ischaemia via RNA/protein complexes.

Authors:  Can Tepeköylü; Uwe Primessnig; Leo Pölzl; Michael Graber; Daniela Lobenwein; Felix Nägele; Elke Kirchmair; Elisabeth Pechriggl; Michael Grimm; Johannes Holfeld
Journal:  J Cell Mol Med       Date:  2016-12-20       Impact factor: 5.310

7.  Safety and efficacy of direct Cardiac Shockwave Therapy in patients with ischemic cardiomyopathy undergoing coronary artery bypass grafting (the CAST-HF trial): study protocol for a randomized controlled trial.

Authors:  Leo Pölzl; Felix Nägele; Michael Graber; Jakob Hirsch; Daniela Lobenwein; Martina Mitrovic; Agnes Mayr; Markus Theurl; Michael Schreinlechner; Matthias Pamminger; Christian Dorfmüller; Michael Grimm; Can Gollmann-Tepeköylü; Johannes Holfeld
Journal:  Trials       Date:  2020-05-30       Impact factor: 2.279

8.  Exposure of zebra mussels to extracorporeal shock waves demonstrates formation of new mineralized tissue inside and outside the focus zone.

Authors:  Katharina Sternecker; Juergen Geist; Sebastian Beggel; Kristin Dietz-Laursonn; Matias de la Fuente; Hans-Georg Frank; John P Furia; Stefan Milz; Christoph Schmitz
Journal:  Biol Open       Date:  2018-07-02       Impact factor: 2.422

9.  Shock Wave Treatment Protects From Neuronal Degeneration via a Toll-Like Receptor 3 Dependent Mechanism: Implications of a First-Ever Causal Treatment for Ischemic Spinal Cord Injury.

Authors:  Daniela Lobenwein; Can Tepeköylü; Radoslaw Kozaryn; Elisabeth J Pechriggl; Mario Bitsche; Michael Graber; Helga Fritsch; Severin Semsroth; Nadia Stefanova; Patrick Paulus; Martin Czerny; Michael Grimm; Johannes Holfeld
Journal:  J Am Heart Assoc       Date:  2015-10-27       Impact factor: 5.501

10.  Low-Intensity Shockwave Therapy (LI-ESWT) in Diabetic Kidney Disease: Results from an Open-Label Interventional Clinical Trial.

Authors:  Sune Moeller Skov-Jeppesen; Knud Bonnet Yderstraede; Boye L Jensen; Claus Bistrup; Milad Hanna; Lars Lund
Journal:  Int J Nephrol Renovasc Dis       Date:  2021-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.